A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

NCT03153085 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma Stage III
Melanoma Stage IV

Interventions

BIOLOGICAL: TBI-1401(HF10)
DRUG: Ipilimumab

Sponsor

Takara Bio Inc.